To determine whether Gdpd3-mediated lysophospholipid metabolism was necessary for disease-relapsing capacity in CML stem cells, we transplanted recipient mice with Gdpd3+/+ or Gdpd3−/− retro-CML-LSK cells in a first-round of BMT and treated the animals with the TKI dasatinib. This evidence concerns the gene GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive.